Claims cover methods of treating any cancer with IMM-101 in combination with anti-PD-L1 or anti-PD1 antibodies

This further US patent will bolster the Company’s strong IP protection around IMM-101

Uxbridge, UK – 18 October 2021 – Immodulon, the immuno-oncology company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 15/738,674 relating to IMM-101, the Company’s investigational treatment comprising heat-killed Mycobacterium obuense, for the treatment of all cancer types.

The allowed claims cover methods of treating any cancer type with IMM-101 in combination with anti-PD1 and/or anti-PD-L1 antibodies. Furthermore, these allowed claims provide protection for treating a range of cancer types, including metastatic cancers, as well as covering various routes of administration of IMM-101. Upon grant, this US patent is expected to expire in 2034.

This allowance follows the granting of five other US patent applications with claims directed to specific cancer types, including sarcoma, melanoma, colorectal and pancreatic cancer. Immodulon intends to conduct further clinical studies related to the allowed claim scope and advance IMM-101 into other cancers with high unmet need.

Cellia K. Habita, M.D., PhD, Chief Executive Officer of Immodulon, commented:
“We are pleased to have received this notice of allowance which greatly expands our US patent protection for IMM-101. These allowed, broad claims cover treatment of all cancer types with IMM-101 in combination with the most commonly prescribed classes of immune checkpoint inhibitors, as well as further claims relating to a large range of specific cancer types and routes of administration. We continue to pursue robust intellectual property protection for IMM-101, with a growing patent estate covering the treatment of cancers with high unmet medical need. This new allowed US patent will support ongoing discussions with third parties as well as facilitate further clinical studies.”

About Immodulon Therapeutics
Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system predominantly via Toll-like receptor 2. It is Immodulon’s vision that IMM-101 will become a backbone immunotherapy across multiple tumour types. Its unique mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and any other standard-of-care treatment of the four major pillars of cancer therapy – immunotherapy, chemotherapy, radio/ablation therapy and surgery – it is also expected to increase their efficacy without compromising patient safety or quality of life. For more information about Immodulon, please visit